Journal: Journal of Medical Virology

Article Title: SARS‐CoV‐2 mRNA Vaccination Induces Neutralizing Antibodies and Type I IFN Changes in People Living With HIV

doi: 10.1002/jmv.71067

Figure Lengend Snippet: Pipeline of the study. PLWH, people living with HIV; PBMCs, peripheral blood mononuclear cells; IFN, interferon.

Article Snippet: All serum samples were assayed for nAbs to IFN‐α2 subtype (Intron; Schering‐Plough, Kenilworth, New Jersey, USA), IFN‐β (Rebif, Serono, Geneva, Switzerland), and IFN‐ω (PBL Interferon Source, Piscataway, USA) in a bioassay based on the IFN‐induced inhibition of the encephalomyocarditis virus (EMCV) cytopathic effect on human lung carcinoma epithelial cells (A549), as previously reported [ ].

Techniques:

Journal: Journal of Medical Virology

Article Title: SARS‐CoV‐2 mRNA Vaccination Induces Neutralizing Antibodies and Type I IFN Changes in People Living With HIV

doi: 10.1002/jmv.71067

Figure Lengend Snippet: Expression levels of IFN‐I in PLWH receiving BNT162b2 COVID‐19 vaccination. Expression levels of genes encoding IFN‐α2 (A), IFN‐β (B), IFN‐ω (C) measured by RT‐Real Time PCR, in PBMCs collected from people living with HIV (PLWH) before the first administration of BNT162b2 vaccine (T0, n = 66), the day of the administration of the second vaccine dose (T1, n = 66), after the administration of the second injection of BNT162b2 vaccine (T2, N = 67) and then more than 1 year after the T2 time‐point (T3, n = 60). The analysis of gene expression differences for IFN‐α2, IFN‐β, and IFN‐ω related to GUS (2 −ΔCt method) was conducted using the maximum number of available observations. Data are shown as natural logarithm (ln) and both median values and interquartile range of gene expression levels are reported. ∗ p < 0.05; ∗∗ p < 0.001; ∗∗∗ p < 0.0001.

Article Snippet: All serum samples were assayed for nAbs to IFN‐α2 subtype (Intron; Schering‐Plough, Kenilworth, New Jersey, USA), IFN‐β (Rebif, Serono, Geneva, Switzerland), and IFN‐ω (PBL Interferon Source, Piscataway, USA) in a bioassay based on the IFN‐induced inhibition of the encephalomyocarditis virus (EMCV) cytopathic effect on human lung carcinoma epithelial cells (A549), as previously reported [ ].

Techniques: Expressing, Real-time Polymerase Chain Reaction, Injection, Gene Expression

Journal: Smart Molecules

Article Title: Endocytosis‐independent cytosolic entry of messenger RNA via fluorous bilayer zippering attenuating Toll‐like receptor signaling and enables ischemic tissue salvage

doi: 10.1002/smo2.70085

Figure Lengend Snippet: Biocompatibilities and immunogenicity of mRNA‐encapsulating polyplexes. (a) Cell viabilities of HUVECs upon 24 h incubation in presence of a variety of mRNA‐encapsulating polyplexes (mean ± s.d., n = 4, ** p < 0.01, student t test). (b) Hemolytic activities of sheep red blood cells upon 2 h incubation with varied concentrated delivery materials (*** p < 0.005; Student's t ‐test, mean ± s.d., n = 4). (c) confocal laser scanning microscopy (CLSM) measurement for assessment of overall cellular internalization of mRNA‐encapsulating polyplexes into RAW264.7 cells. (d) Interferon‐β (IFN‐β): at 4 h post incubation, the expression levels of inflammatory molecules were measured with qRT‐PCR. (e) Interleukin‐8 (IL‐8): at 4 h post incubation, the expression levels of inflammatory molecules were measured with qRT‐PCR. (** p < 0.01, *** p < 0.005; Student's t ‐test, n = 4).

Article Snippet: Culture supernatants (100 μL/well) were harvested and assayed for IFN‐α using the Mouse IFN‐α ELISA Kit (PBL Interferon Source) according to the manufacturer's instructions.

Techniques: Immunopeptidomics, Incubation, Confocal Laser Scanning Microscopy, Expressing, Quantitative RT-PCR

Journal: Smart Molecules

Article Title: Endocytosis‐independent cytosolic entry of messenger RNA via fluorous bilayer zippering attenuating Toll‐like receptor signaling and enables ischemic tissue salvage

doi: 10.1002/smo2.70085

Figure Lengend Snippet: Revascularization in hindlimbs by local dosage of mVEGF‐encapsulating polyplexes. (a) Therapeutic scheme. (b) Anatomy of the established hindlimb ischemia model. Ligations were made in the femoral artery at the proximal and distal sites. (c) Angiogenesis in mouse hindlimbs post ligation. (d) Visualization of blood flow by Laser Speckle Flowgraphy on Day 28 post‐dosage of mVEGF therapeutics (mVEGF: 10 μg). The magnified inset images captured by intravital confocal laser scanning microscopy (CLSM), revealing vasculature details by intravenous dosage of FITC‐dextran (MW: 10 kDa). (e) Estimation of blood perfusion volume based on quantification by laser speckle flowgraphy on Day 28 post‐dosage of mVEGF therapeutics (mVEGF: 10 μg). The data were represented as the mean ± standard deviations (s.d.) ( n = 5). (* p < 0.05, ** p < 0.01, student t test). (f) Quantification of the expressed VEGF protein on day 4 post dosage by ELISA.

Article Snippet: Culture supernatants (100 μL/well) were harvested and assayed for IFN‐α using the Mouse IFN‐α ELISA Kit (PBL Interferon Source) according to the manufacturer's instructions.

Techniques: Ligation, Confocal Laser Scanning Microscopy, Enzyme-linked Immunosorbent Assay